VR Adviser, LLC
- SEC CIK
- 0001615982
- Latest filing
- Aug 14, 2026
Holdings in Q4 2021
Holdings as of Dec 31, 2021, filed Feb 14, 2022. Long positions only; changes compare share counts with Q3 2021.
- Positions
- 26
- 0 vs. Q3 2021
- Portfolio value
- $731.5M
- −$47.0M (−6.0%) vs. Q3 2021
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| CRVSCorvus Pharmaceuticals, Inc. | COM | 250,000 | $603.0K | 0.1% | −3,177,461−92.7% | Reduced | History |
| ATXSAstria Therapeutics, Inc. | COM | 538,999 | $2.90M | 0.4% | 00.0% | Unchanged | History |
| AKYAAkoya Biosciences, Inc. | COM | 400,000 | $6.12M | 0.8% | 00.0% | Unchanged | History |
| CVRXCVRx, Inc. | COM | 533,370 | $6.52M | 0.9% | 00.0% | Unchanged | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 816,651 | $7.64M | 1.0% | −719,542−46.8% | Reduced | History |
| Affimed N VN01045108 | COM | 1,428,571 | $7.89M | 1.1% | +1,428,571 | New | – |
| COGTCogent Biosciences, Inc. | COM | 1,088,817 | $9.34M | 1.3% | 00.0% | Unchanged | History |
| ATYRaTYR PHARMA INC | COM NEW | 1,565,000 | $11.7M | 1.6% | 00.0% | Unchanged | History |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 1,127,272 | $12.7M | 1.7% | 00.0% | Unchanged | History |
| LONALeonaBio, Inc. | COM | 1,000,000 | $13.0M | 1.8% | −196,196−16.4% | Reduced | History |
| KNTEKinnate Biopharma Inc. | COM | 773,014 | $13.7M | 1.9% | −700,000−47.5% | Reduced | History |
| NUVLNuvalent, Inc. | COM | 803,951 | $15.3M | 2.1% | 00.0% | Unchanged | History |
| LENZLENZ Therapeutics, Inc. | COM | 1,612,617 | $20.0M | 2.7% | 00.0% | Unchanged | History |
| KDNYChinook Therapeutics, Inc. | COM | 1,283,821 | $20.9M | 2.9% | +1,283,821 | New | History |
| VTGNVistagen Therapeutics, Inc. | COM NEW | 16,047,286 | $31.3M | 4.3% | 00.0% | Unchanged | History |
| LIANYLianBio | SPONSORED ADS | 5,378,341 | $33.1M | 4.5% | +5,378,341 | New | History |
| TCDATricida, Inc. | COM | 3,494,851 | $33.4M | 4.6% | +3,104,144+794.5% | Added | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 865,116 | $33.4M | 4.6% | −233,058−21.2% | Reduced | History |
| MRNSMarinus Pharmaceuticals, Inc. | COM NEW | 2,880,096 | $34.2M | 4.7% | +238,287+9.0% | Added | History |
| VRDNViridian Therapeutics, Inc. | COM | 1,852,919 | $36.6M | 5.0% | +1,833,424+9,404.6% | Added | History |
| WHWKWhitehawk Therapeutics, Inc. | COM | 1,529,402 | $36.9M | 5.0% | 00.0% | Unchanged | History |
| GHRSGH Research PLC | ORDINARY SHARES | 2,021,985 | $47.2M | 6.4% | +379,689+23.1% | Added | History |
| RLMDRelmada Therapeutics, Inc. | COM | 2,270,072 | $51.1M | 7.0% | +882,352+63.6% | Added | History |
| TVTXTravere Therapeutics, Inc. | COM | 1,994,997 | $61.9M | 8.5% | +262,587+15.2% | Added | History |
| ACRSAclaris Therapeutics, Inc. | COM | 4,563,962 | $66.4M | 9.1% | 00.0% | Unchanged | History |
| TILInstil Bio, Inc. | COM | 6,865,076 | $117.5M | 16.1% | 00.0% | Unchanged | History |
Sold out since Q3 2021 (3)
Positions held at the end of Q3 2021 that are gone from this filing.